Clinical Trial Update: Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC [Phase 2]

View source ↗

Summary

Phase 2 trial update for Nesiritide (Natrecor) in transplant-eligible management of congestive heart failure was terminated with results posted in 2008.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Transplantation
• Heart Failure
• Renal Failure
• Renal Insufficiency

Drugs mentioned

• Natrecor (nesiritide)

Snippet

Sponsor: Scios, Inc. | Conditions: Congestive Heart Failure, Cardiac Transplantation | Phase 2 | Status: TERMINATED | Results posted: 2008-12-05